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Abstract 
We present a case of Trichoderma fungemia with pulmonary involvement in a multiple myeloma 
patient, who was severely immunocompromised and heavily treated with high-dose melphalan, and 
underwent autologous hematopoietic cell transplantation. This is the first report, to our knowledge, 
of proven Trichoderma fungemia, defined by published criteria, successfully treated with 
voriconazole. 
Despite recent advances in the therapy of infectious diseases, opportunistic mold disseminated 
infections remain a major cause of morbidity and mortality in patients with hematological 
malignancies and in transplant recipients, and prompt diagnosis and treatment are crucial. During 
the past 15 years, the epidemiology of invasive fungal infections has greatly changed. Although 
Candida species constitute the third to fourth most common cause of nosocomial bloodstream 
infection, Aspergillus species remain the most common cause of lethal lung infections in 
hematopoietic transplant recipients, and Cryptococcus neoformans is the most common cause of 
fungal-related mortality in human immunodeficiency virus patients. 
However, less common but emerging fungal pathogens also cause morbidity and mortality in the 
increasingly expanding immunocompromised patient population. These pathogens include septate 
filamentous fungi, such as Fusarium, Scedosporium, and Trichoderma species, and various 
dematiaceous molds [1, 2]. 
The 7 currently identified Trichoderma species are distributed worldwide, usually found in humid 
soil and decaying biological material, and rarely infect humans. In the immunocompromised host, 
Trichoderma infections are characterized by the presence of septate hyphae in tissue sections, for 
which differential diagnosis with invasive aspergillosis may be difficult. Few cases have been 
reported and included localized as well as disseminated infections, with mortality rates as high as 
50%. Principal sources of contamination were ambient air, water-related sites, food, and venous 
catheters [3-16]. 
Case report 
A 45-year-old Caucasian male was diagnosed with micromolecular multiple myeloma. At 
diagnosis, the patient presented with nephrotic syndrome with proteinuria >5 g/day and hyaline 
casts associated with hypertension. Other than renal failure, no signs of end-organ damage, such as 
hypercalcemia, anemia, and/or bone lesions, were observed. A bone marrow aspirate revealed a 
monoclonal plasma cell infiltration of 15%. Prompt treatment was instituted with 4 cycles of 
bortezomib, adriamycin, and dexamethazone followed by cyclophosphamide and recombinant 
human granulocyte colony-stimulating factor (G-CSF) mobilized peripheral hematopoietic cell 
collection. A very good partial remission was reached [17]. 
One month later, the patient was admitted to the Transplant Unit to receive high-dose melphalan 
and autologous hematopoietic cell transplantation. Upon admission, he was in good general 
condition with no fever and no signs of infections. Routine pretransplant chest x-ray showed no 
abnormalities. Hemoglobin levels, white blood cell and platelet counts, and blood biochemistry 
profile were normal. Melphalan was administered at the total dose of 440 mg (200 mg/m
2
) on day 
−2 and 5 × 106 autologous CD34+ cells/kg were reinfused on day 0. From day +3 post transplant, 
G-CSF was administered for 10 days to reduce the duration of neutropenia. Antimicrobial 
prophylaxis consisted of acyclovir and fluconazole. 
On day +5, the patient developed melphalan-induced pancytopenia with undetectable neutrophils by 
hemocytometer. On day +8, fever up to 38.1°C was observed. Fever work-up included central and 
peripheral venous blood cultures and chest x-ray, which showed no infiltrates. Empirical treatment 
with ceftazidime was initiated, at the dose of 2 g 3 times a day. On day +10, pulse oximetry showed 
an O2 saturation of 90% that required oxygen therapy with nasal cannula. Fever became intermittent 
with spikes up to 39°C. Levofloxacin at 500 mg/day was added and the central venous catheter 
(CVC) removed and replaced with a new one at a different insertion site. Cultures from the CVC tip 
remained negative for fungal and bacterial pathogens. 
Moreover, given the onset of right flank pain, a lung high-resolution computed tomography 
(HRCT) scan was performed and showed a parenchymal nodular opacity with a halo sign associated 
with pleural effusion, suggestive of invasive mold infection (Fig. 1A). No neurological signs or 
symptoms were observed. Abdominal ultrasonography showed no signs of abscess or deep tissue 
infiltration suggestive of fungal infection. Serum galactomannan monitoring was negative. 
 Figure 1. High-resolution computed tomography scans of the lungs: nodular opacity with halo sign in the 
right lung with plural effusion at 1 month post transplant (A); disappearance of the ground-glass halo sign 
and major reduction in the nodular opacity at 2 months post transplant (B); complete resolution of the lung 
infiltrate at 12 months post transplant (C). 
However, after 3 days of incubation at 37°C on Sabouraud dextrose agar, blood cultures drawn on day +8 
from the basilic CVC and from a peripheral vein yielded a filamentous fungus (Fig. 2A). Initially, white 
colonies became wooly and yellow-green within a week. At first, microscopic examination showed septate 
hyaline hyphae and, after a few days, conidiophores, phialides, and conidia were observed. Conidiophores 
were hyaline, branched with a pyramidal arrangement, and phyalide were hyaline, flask-shaped, and 
producing round, smooth green conidia. The fungus was identified as Trichoderma species by colony aspect 
on Sabouraud dextrose agar and by morphological features of the conidia and phialides. 
 Figure 2. Microscopic appearance of Trichoderma species in tape mount preparation (A); antifungal 
susceptibility tests: fluconazole (B); and voriconazole (C). 
Microscopic identification was confirmed by sequence analysis of internal transcribed spacer ITS2 
rDNA [18]. The acquired sequence, compared with those reported in the Entrez Nucleotide 
Database of the National Center for Biotechnology Information using the BLAST algorithm to 
determine sequence homology, showed 100% homology with Trichoderma species. Antifungal 
susceptibility tests were performed by the Epsilometer test method as per manufacturer's 
instructions, compared with ATCC204350 Aspergillus fumigatus (Fig. 2B and C). Minimal 
inhibitory concentration values obtained were as follows: fluconazole >256 μg/mL, itraconazole 
>32 μg/mL, voriconazole 0.125 μg/mL, and caspofungin 0.047 μg/mL. 
Intravenous voriconazole was started at a loading dose of 400 mg twice a day on the first day, 
followed by maintenance dose at 200 mg twice a day. Voriconazole plasma levels remained within 
the therapeutic range of 1000–5500 ng/mL (1622 ng/mL on day +22) [19]. A bronchoalveolar 
lavage was performed 3 days after the start of voriconazole. Cultures were negative for fungal, 
bacterial, and viral pathogens, as well as for galactomannan. Repeated blood cultures from CVC on 
day +15 were negative. 
After the start of voriconazole, the patient's respiratory symptoms gradually improved. Meanwhile, 
blood counts recovered up to leukocytes of 2260/mm
3
, neutrophils of 1390/mm
3
, and lymphocytes 
of 180/mm
3
. On day +32, a repeated lung HRCT scan showed the disappearance of the ground-
glass halo sign and shrinking of the nodular opacity. 
The patient was eventually discharged from the Transplant Unit on day +42 post transplant in good 
general condition. Voriconazole therapy was continued up to 8 months post transplant. No liver or 
neurological toxicities were observed. On follow-up lung HRCT scans in the outpatient service, the 
right lung infiltrate gradually shrank and completely healed at 1 year post transplant (Fig. 1B and 
C). 
Discussion 
Trichoderma species are ubiquitous molds associated with rare, though severe, localized or 
disseminated infections in the immunocompromised host. Clinical manifestations may greatly vary 
and include pulmonary mycetoma, ulceronecrotic skin lesions, brain or liver abscess, endocarditis, 
sinusitis, necrotizing stomatitis, and dialysis-related peritonitis. Trichoderma longibrachiatum, the 
main human pathogen within the genus, has been isolated in 18 of the total 37 patients described in 
the literature [3-16]. Of note, invasive infections caused by this pathogen have more frequently been 
reported in patients with hematological or solid organ malignancies on immunosuppressive 
therapies and in patients on ambulatory peritoneal dialysis [3, 7, 12, 13]. Treatment usually requires 
removal of the foreign bodies, systemic antifungal therapy, treatment of the underlying disease, and 
in case of isolated mycetoma, surgical excision. Nevertheless, the prognosis remains poor. 
To our knowledge, despite well-documented Trichoderma systemic disseminations, only 2 cases of 
positive blood cultures have so far been described [14, 15]. Here, we reported a case of proven 
invasive fungal infection supported by both imaging (halo sign at HRCT scan) and, importantly, 
proven by both central and peripheral venous blood cultures [20, 21]. In particular, blood cultures 
were a crucial diagnostic tool, as they were positive on samples collected before the occurrence of 
pulmonary symptoms and allowed for the prompt start of susceptibility testing-based antifungal 
therapy. 
Voriconazole was preferred to caspofungin as per Center guidelines on the treatment of mold 
infections and its distribution through the hemato-encephalic barrier. Antifungal combination 
therapy as front-line therapy was avoided, given the lack of convincing data on the advantage of its 
use [21, 22]. Single-agent therapy with voriconazole was well tolerated, and cured the infection. 
An increased awareness is needed of this uncommon, but frequently fatal, fungal infection other 
than Aspergillus species, and it should be considered in immunosuppressed patients, as timely 
diagnostic work-up, including imaging studies and blood cultures, allowed a prompt diagnosis of a 
potentially life-threatening infection. In our experience, voriconazole was efficient in the treatment 
of fungal pneumonia associated with Trichoderma fungemia in a severely immunocompromised 
patient. 
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